Summit Therapeutics SMMT

$ 18.52 -0.56%

Quarterly report 2024-Q3
added 10-30-2024

Summit Therapeutics Income Statement 2011-2024 | SMMT

Annual Income Statement Summit Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	2.24 B	286 M	361 M	417 M	195 M	804 M	791 M	390 M	-	-	-	-	-
Shares	620 M	193 M	132 M	69.5 M	85.7 M	65.4 M	61.5 M	59.1 M	-	-	-	-	-
Historical Prices	3.61	1.48	2.74	6.77	1.38	2.3	11.7	12.2	6.75	-	-	-	-
Net Income	-615 M	-78.8 M	-88.6 M	-52.7 M	9.87 M	-10.1 M	-26.7 M	-24.3 M	-17.1 M	-10.1 M	-6.67 M	-4.23 M	-7.42 M
Revenue	-	705 K	1.81 M	860 K	56.4 M	36 M	2.88 M	-	-	2.27 M	2.87 M	2.77 M	1.21 M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	56.4 M	35.9 M	-	-	-	2.27 M	2.87 M	-	-
Operating Income	-610 M	-72.1 M	-86.2 M	-53.2 M	-27.5 M	-28.4 M	-	-	-	-	-	-	-
Interest Expense	-252 K	304 K	242 K	255 K	291 K	1.54 M	-	-	-	-	-	-	-
EBITDA	-609 M	-71.7 M	-85.9 M	-52.9 M	9.53 M	-15.1 M	-30.3 M	-29.4 M	-19.4 M	-11 M	-5.5 M	-4.37 M	5.9 M
Operating Expenses	611 M	87.2 M	109 M	73.4 M	47.3 M	51.2 M	33.3 M	29.4 M	-	13.3 M	8.51 M	-	-
General and Administrative Expenses	30.3 M	26.7 M	23.6 M	19.2 M	15.4 M	13.8 M	9.62 M	7.45 M	6.8 M	3.24 M	2.77 M	2.31 M	2.68 M

All numbers in USD currency

Quarterly Income Statement Summit Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	727 M	708 M	702 M	702 M	698 M	698 M	378 M	211 M	209 M	140 M	140 M	98 M	99 M	92.1 M	82.8 M	82.6 M	67.2 M	67.2 M	67.2 M	67.2 M	32.1 M	32.1 M	-	14.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-56.3 M	-60.4 M	-43.5 M	-	-21.3 M	-14.7 M	-542 M	-	-21.4 M	-16.8 M	-21.4 M	-	-19.6 M	-24.4 M	-17.5 M	-	-17.7 M	-15.3 M	-6.13 M	-	-6.38 M	-6.68 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	220 K	235 K	250 K	-	1.31 M	57 K	192 K	-	181 K	170 K	324 K	-	148 K	156 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-58.4 M	-59.6 M	-42.4 M	-	-20.5 M	-15.8 M	-537 M	-	-16.9 M	-12.7 M	-22.2 M	-	-19.5 M	-23.7 M	-16.9 M	-	-16.9 M	-15.4 M	-9.34 M	-	-6.19 M	-6.74 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	-	-	-64 K	-5 K	417 K	-	46 K	-14 K	152 K	-	-	216 K	-	-	416 K	-	-	-	-75 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-42.4 M	-	-	-	-537 M	-	-16.7 M	-12.5 M	-22.1 M	-	-19.2 M	-23.6 M	-16.8 M	-	-16.7 M	-15.2 M	-9.27 M	-	-5.92 M	-6.74 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	58.1 M	59.8 M	42.6 M	-	20.8 M	15.8 M	538 M	-	22.6 M	15.9 M	27.2 M	-	25.6 M	29.9 M	22.6 M	-	21.4 M	19.3 M	16.5 M	-	12.6 M	13.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	20.4 M	14 M	11.7 M	-	5.43 M	6.32 M	6.94 M	-	5.57 M	6.93 M	6.66 M	-	5.66 M	5.98 M	4.18 M	-	6.85 M	5.77 M	3.57 M	-	2.68 M	2.14 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency